Research and translational progress in tumor immunotherapy targeting immune checkpoint B7-H3
10.3969/j.issn.1000-484X.2025.07.015
- VernacularTitle:靶向免疫检查点B7-H3的肿瘤免疫治疗研究和转化进展
- Author:
Wenjing XIANG
1
;
Hanqing CHEN
;
Ningning CAI
;
Yu SHEN
;
Xueguang ZHANG
;
Fengqing FU
Author Information
1. 苏州大学附属第一医院江苏省临床免疫研究所,苏州 215000;苏州大学药学院,苏州 215000
- Publication Type:Journal Article
- Keywords:
B7-H3(CD276);
Immune checkpoint molecules;
Therapeutic antibodies;
Tumor immunotherapy
- From:
Chinese Journal of Immunology
2025;41(7):1638-1646
- CountryChina
- Language:Chinese
-
Abstract:
Tumor-targeted therapy is a vital approach in precision medicine,selection of target molecule is a key element in tumor-targeted therapy.B7-H3(CD276),as an immune checkpoint molecule selectively highly expressed on tumor cells,is a crucial molecule involved in regulation of tumor immunity.Numerous recent studies have found that B7-H3,in addition to its immune check-point function,also participates in regulation of malignant biological behaviors of tumor cells and is considered to have great potential as a pan-cancer universal drug target.Current immunotherapeutic strategies targeting B7-H3 primarily include development of block-ing monoclonal antibodies(Blocking mAb),antibody-drug conjugate(ADC),chimeric antigen receptor(CAR)T/NK cell therapies,monoclonal antibody dependent cellular cytotoxicity(ADCC)drugs,radionuclide drug conjugates(RDC),bispecific/trispecific anti-body(BsAb/TriAb),and antibody cytokine drug combinations,among others.These strategies aim to enhance body's immune re-sponse to cancer through various mechanisms,thereby inhibiting tumor growth and metastasis.Multiple preclinical and clinical studies have shown that immunotherapy targeting B7-H3 has potential therapeutic value.Therefore,this article mainly reviews the latest status of development of tumor immunotherapy drugs targeting B7-H3 molecule.
